FDA clears Eli Lilly's oral GLP-1 Foundayo for obesity

FDA approved Eli Lilly's oral GLP-1 obesity drug orforglipron (brand name Foundayo) on April 1. It's the first oral GLP-1 obesity drug that doesn't require food or water restrictions, squaring off directly against injectables Wegovy and Zepbound.